Schizophrenia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Schizophrenia stocks.

Recent Signals

Date Stock Signal Type
2021-04-09 ACAD NR7 Range Contraction
2021-04-09 ACAD New 52 Week Low Weakness
2021-04-09 ACAD Narrow Range Bar Range Contraction
2021-04-09 ACAD New 52 Week Closing Low Bearish
2021-04-09 ACAD Calm After Storm Range Contraction
2021-04-09 ALKS 200 DMA Support Bullish
2021-04-09 ALKS Bollinger Band Squeeze Range Contraction
2021-04-09 ALKS MACD Bullish Signal Line Cross Bullish
2021-04-09 ATHX Fell Below 20 DMA Bearish
2021-04-09 ATHX 180 Bearish Setup Bearish Swing Setup
2021-04-09 AZN Bollinger Band Squeeze Range Contraction
2021-04-09 AZN Crossed Above 20 DMA Bullish
2021-04-09 AZN Crossed Above 50 DMA Bullish
2021-04-09 BLRX NR7 Range Contraction
2021-04-09 BLRX Narrow Range Bar Range Contraction
2021-04-09 BMY Crossed Above 20 DMA Bullish
2021-04-09 BMY Cup with Handle Other
2021-04-09 BMY Bullish Engulfing Bullish
2021-04-09 BMY Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-04-09 CERE Narrow Range Bar Range Contraction
2021-04-09 CNCE NR7 Range Contraction
2021-04-09 CNCE New 52 Week Low Weakness
2021-04-09 CNCE New 52 Week Closing Low Bearish
2021-04-09 DRRX Narrow Range Bar Range Contraction
2021-04-09 ENDP Lower Bollinger Band Walk Weakness
2021-04-09 JAZZ Stochastic Buy Signal Bullish
2021-04-09 JAZZ Doji - Bullish? Reversal
2021-04-09 JAZZ Lizard Bullish Bullish Day Trade Setup
2021-04-09 KRTX MACD Bearish Signal Line Cross Bearish
2021-04-09 KRTX 20 DMA Resistance Bearish
2021-04-09 KRTX NR7 Range Contraction
2021-04-09 KRTX Fell Below 50 DMA Bearish
2021-04-09 LLY MACD Bullish Signal Line Cross Bullish
2021-04-09 NERV 180 Bearish Setup Bearish Swing Setup
2021-04-09 PRTC Narrow Range Bar Range Contraction
2021-04-09 RVPH New 52 Week Closing Low Bearish
2021-04-09 RVPH New 52 Week Low Weakness
2021-04-09 VNDA Fell Below 20 DMA Bearish
2021-04-09 XTLB Doji - Bullish? Reversal
2021-04-09 XTLB Bollinger Band Squeeze Range Contraction
2021-04-09 XTLB 1,2,3 Pullback Bullish Bullish Swing Setup
2021-04-09 XTLB Fell Below 50 DMA Bearish
2021-04-09 ZGNX Doji - Bullish? Reversal

Recent News for Schizophrenia Stocks

Date Stock Title
Apr 10 AZN Could AstraZeneca's Nasal COVID Vaccine Development Zap Altimmune's Prospects?
Apr 9 ACAD HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Updates ACAD, UI Investors on Securities Fraud Investigations, Encourages Investors with Losses to Contact the Firm
Apr 9 AZN Vaccitech, startup behind AstraZeneca-Oxford's COVID-19 vaccine, files for U.S. IPO
Apr 9 JAZZ Jazz Securities Designated Activity Company -- Moody's assigns Ba2 to Jazz Pharma's new secured credit facilities; negative outlook
Apr 9 AZN Oxford-AstraZeneca Vaccine Designer to Sell Shares in U.S. IPO
Apr 9 AZN "A big hit to the vaccine campaign": Doctor on Johnson & Johnson's vaccine delivery plunge
Apr 9 AZN Michigan Seeks Aid Amid Surge; EU Reviews J&J Shot: Virus Update
Apr 9 BMY Bristol Myers' (BMY) Opdivo Combo Positive in ESCC Study
Apr 9 LLY Top Stock Reports for Oracle, Eli Lilly & BP
Apr 9 AZN European Union Looks To Buy 1.8B Pfizer-BioNTech COVID-19 Vaccine Doses From 2022: Reuters
Apr 9 AZN Pfizer’s vaccine EUA expansion request is ‘extremely welcomed’: Doctor
Apr 9 AZN UPDATE 3-J&J COVID-19 vaccine under EU review over blood clots
Apr 9 BMY Sanofi confirms partial response for cancer therapy in mid-stage study
Apr 9 AZN J&J Covid Vaccine Reviewed by EU Regulator After Blood Clots
Apr 9 AZN Why Moderna Stock Is Jumping Today
Apr 9 AZN Johnson & Johnson's COVID-19 Vaccine Under Review At EMA For Blood Clots, AstraZeneca Probe Expanded
Apr 9 AZN Why Shares Of Johnson & Johnson Are Under Pressure Today?
Apr 9 AZN ‘The Michigan spike is something we should be nervous about’: Doctor
Apr 9 AZN New research ties AstraZeneca’s COVID-19 shots with rare blood clots
Apr 9 AZN Trouble Is Brewing For J&J's Covid Vaccine — What You Need To Know

Schizophrenia is a mental disorder characterized by abnormal behavior, strange speech and a decreased ability to understand reality. Other symptoms include false beliefs, unclear or confused thinking, hearing voices that do not exist, reduced social engagement and emotional expression and lack of motivation. People with schizophrenia often have additional mental health problems such as anxiety, depressive or substance-use disorders. Symptoms typically come on gradually, begin in young adulthood and in many cases never resolve.The causes of schizophrenia include environmental and genetic factors. Possible environmental factors include being raised in a city, cannabis use during adolescence, certain infections, the age of a person's parents, and poor nutrition during pregnancy. Genetic factors include a variety of common and rare genetic variants. Diagnosis is based on observed behavior, the person's reported experiences and reports of others familiar with the person. During diagnosis, a person's culture must also be taken into account. As of 2013, there is no objective test. Schizophrenia does not imply a "split personality" or dissociative identity disorder, conditions with which it is often confused in public perception.The mainstay of treatment is antipsychotic medication, along with counselling, job training and social rehabilitation. It is unclear whether typical or atypical antipsychotics are better. In those who do not improve with other antipsychotics, clozapine may be tried. In more serious situations where there is risk to self or others, involuntary hospitalization may be necessary, although hospital stays are now shorter and less frequent than they once were.About 0.3% to 0.7% of people are affected by schizophrenia during their lifetimes. In 2013, there were an estimated 23.6 million cases globally. Males are more often affected and on average experience more severe symptoms. About 20% of people eventually do well, and a few recover completely; about 50% have lifelong impairment. Social problems, such as long-term unemployment, poverty and homelessness, are common. The average life expectancy of people with the disorder is 10–25 years less than that of the general population. This is the result of increased physical health problems and a higher suicide rate (about 5%). In 2015, an estimated 17,000 people worldwide died from behavior related to, or caused by, schizophrenia.

More about Schizophrenia
Browse All Tags